Compare IDCC & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | BLCO |
|---|---|---|
| Founded | 1972 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Ophthalmic Goods |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.1B |
| IPO Year | 2007 | 2022 |
| Metric | IDCC | BLCO |
|---|---|---|
| Price | $337.94 | $18.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $412.50 | $18.45 |
| AVG Volume (30 Days) | 165.9K | ★ 356.1K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.51 | N/A |
| Revenue | $307,404,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | $3.38 | $5.59 |
| P/E Ratio | $60.94 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $249.14 | $13.77 |
| 52 Week High | $412.60 | $18.92 |
| Indicator | IDCC | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 71.26 |
| Support Level | $330.55 | $16.26 |
| Resistance Level | $336.25 | $18.92 |
| Average True Range (ATR) | 10.68 | 0.42 |
| MACD | -3.87 | 0.07 |
| Stochastic Oscillator | 54.98 | 76.18 |
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.